An observational study in Type 1 Diabetes Mellitus, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by DCB Research AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 9th largest by enrollment of the 18 observational ones that give a count, is one of 7 that started in 2023, is one of 18 observational ones, and was the 65th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
DCB Research AG is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
DCB Research AG has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the impact of menstrual cycle phases on insulin sensitivity, glycaemic control, and insulin requirements in women with type 1 diabetes (T1D). It aims to quantify differences between the follicular and luteal phases using data from the Tidepool Data Platform. Key endpoints include modelled insulin sensitivity, mean glucose, Time in Range (TIR), and total insulin dose.
Secondary objectives include assessing phase-specific variability in the endpoints and differences between participants.
The study follows a decentralized, anonymized data collection approach, with participants using continuous glucose monitors (CGMs) and insulin pumps or smart pens. Glycaemic outcomes and insulin requirements will be compared across menstrual cycle phases using linear mixed-effects models to account for repeated measures within individuals. Cycle phase-specific variation in insulin sensitivity will be quantified using a hierarchical Bayesian state-space model, which estimates a latent insulin sensitivity parameter from CGM time series data while accounting for measurement noise and temporal dynamics.
The findings are expected to improve understanding of glycaemic dynamics across the menstrual cycle and inform future diabetes management strategies.
This study includes adults (18+) living with type 1 diabetes (T1D) who use a continuous glucose monitoring (CGM) system and either an insulin pump or a smart pen for insulin delivery. Participants must be willing to upload diabetes-related data to the Tidepool Data Platform, track and share their menstrual cycle data, and provide consent for their anonymized data to be used in research.
Inclusion criteria
People are eligible to participate in the study if they:
The study cohort consists of women with type 1 diabetes (T1D) who use continuous glucose monitoring (CGM) and insulin pumps to manage their diabetes. Participants will anonymously upload their diabetes management data, along with self-reported menstrual cycle information.
Insulin sensitivity
Insulin sensitivity quantified by using a hierarchical Bayesian state-space model that estimates a latent insulin sensitivity parameter from CGM time series data.
Time frame: Between 1 and 12 months
Mean glucose
Mean daily glucose based on CGM data
Time frame: Between 1 and 12 months
Time in range (TIR)
Mean daily TIR based on CGM data
Time frame: Between 1 and 12 months
Time above range (TAR)
Mean daily TAR based on CGM data
Time frame: Between 1 and 12 months
Time belwo range (TBR)
Mean daily TBR based on CGM data
Time frame: Between 1 and 12 months
Total daily insulin
Mean daily total insulin based on insulin pump data
Time frame: Between 1 and 12 months
Total basal insulin
Mean daily total basal insulin based on insulin pump data
Time frame: Between 1 and 12 months
Total bolus insulin
Mean daily total bolus insulin based on insulin pump data
Time frame: Between 1 and 12 months
Plan to share: Undecided
Ran from Dec 2023 to primary completion in Dec 2024, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DCB Research AG